ArticlePLoS neglected tropical diseases2025
Transcriptional and cytokine signatures of Mycobacterium abscessus complex pulmonary disease during disease progression and treatment.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- ERS Congress 2025: highlights from the Respiratory Infections Assembly.ERJ open research · 2026Article
- Animal models of Mycobacterium abscessus pulmonary infection phenotypes: What are we modeling?PLoS pathogens · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMycobacterium abscessus complex pulmonary disease (MABC-PD) is a chronic and often relapsing disease with considerable morbidity, especially among individuals with other chronic pulmonary conditions. A major clinical challenge lies in distinguishing infection-related symptoms from underlying lung disease and identifying reliable prognosticators to guide treatment decisions and monitoring therapeutic response. METHODOLOGY/PRINCIPAL
findingsTo address the gaps in clinically relevant indicators, we profiled whole blood transcriptome and 45 plasma proteins of MABC-PD patients across different disease and treatment phases. Whole blood bulk RNA-sequencing revealed that MABC-PD patients with progressive disease exhibited elevated expression of genes related to innate immune and inflammatory responses, with reduced abundance of genes associated with peripheral T and NK cells. Among the 45 plasma cytokines and chemokines profiled, plasma levels of TNFSF10 were significantly reduced, while IFNγ, interleukin-17F (IL17F) and IL17C were elevated in patients with disease progression, despite the reduced abundance of peripheral T and NK cell-associated genes, suggesting recruitment of activated T cells to infection sites in the lungs during disease progression. Receiver operating characteristic (ROC) curve analysis of IFNγ and IL17F demonstrated strong predictive performance for differentiating patients with disease progression from healthy controls, with AUCs of 0.946 (95% CI 0.829-1.000) and 0.875 (95% CI 0.6699-1), respectively.
conclusionsThese findings provide insights into the immune profiles of MABC-PD patients during disease progression and suggest that T cell-associated cytokines, such as IFNγ and IL17F, could serve as useful biomarkers for identifying those under watchful waiting or post-treatment who are at risk of disease progression, thereby aiding in more timely and targeted therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.